A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma

NCT04763408 · clinicaltrials.gov ↗

COMPLETED

Status

335

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Lenvatinib
DRUG: Sorafenib

Sponsor

Eisai Inc.